| 新辅助化疗联合保肢手术治疗骨肉瘤的疗效 |
| 投稿时间：2015-04-20 修订日期：2015-06-15 点此下载全文 |
| 引用本文：余强,杨浩森,王彦川,刘佶瑗,汪瑜.新辅助化疗联合保肢手术治疗骨肉瘤的疗效[J].医学研究杂志,2016,45(4):134-137,153 |
| DOI：
10.11969/j.issn.1673-548X.2016.04.035 |
| 摘要点击次数: 1014 |
| 全文下载次数: 811 |
|
|
| 中文摘要:目的 探讨含洛铂的新辅助动脉灌注化疗联合保肢手术治疗骨肉瘤患者的临床近远期疗效。方法 选取2006年1月~2012年3月间笔者医院骨科收治的84例四肢骨肉瘤患者为研究对象,按照治疗方式的不同随机分为观察组和对照组,每组各42例。观察组患者采用含洛铂的新辅助动脉灌注化疗联合保肢手术治疗,而对照组患者则采用传统保肢手术联合术后化疗,分别比较两组患者的近远期疗效。结果 观察组患者的总体有效率为92.86%(39/42)显著高于对照组的76.19%(32/42)(χ2=4.459, P=0.035);而且,观察组的肢体Enneking评分值和优良率也均明显高于对照组(t=2.408, P=0.018;χ2=4.366, P=0.037);两组患者的不良反应发生率分别为28.57%(12/42)和33.33%(14/42),两组间比较差异无统计学意义(χ2=0.637, P=0.223);随访结果显示,观察组1、2、3年生存率依次为97.67%、90.70%和83.72%,对照组则依次为95.24%、83.33%、57.14%。两组患者第1、2年生存率比较差异无统计学意义(P>0.05),但观察组3年生存率却显著高于对照组(χ2=8.400,P=0.004);而且,观察组的总生存时间显著高于对照组(t=15.531, P=0.000)。且局部复发率与转移率也明显低于对照组(χ2=5.143, P=0.023)。结论 含洛铂的新辅助动脉灌注化疗联合保肢手术对骨肉瘤具有良好的近远期疗效。 |
| 中文关键词:骨肉瘤 保肢手术 洛铂 新辅助化疗 动脉灌注 |
| |
| Curative Effect of of Neoadjuvant Chemotherapy Combined with Limb Salvage Operation for Treatment of Osteosarcoma |
|
|
| Abstract:Objective To investigate the curative effect of combination of lobaplatin neoadjuvant arterial infusion chemotherapy and limb salvage operation for treatment of osteosarcoma. Methods The 84 cases of osteosarcoma from January 2006 to March 2012 in our hospital were selected as the research object, and were randomly divided them into observation group and control group according to the different treatments, with 42 cases in each group. The patients in the observation group were treated by lobaplatin neoadjuvant arterial infusion chemotherapy combined with limb salvage operation, while the patients of control group were treated with traditional salvage operation and postoperative chemotherapy. Short and long term curative effects were observed and compared. Results The general effective rate of observed group was 92.86% (39/42), showing significantly higher than that of control group at 76.19% (32/42) (χ2=4.459, P=0.035). The Enneking score and the excellent rate of observation group were also significantly higher than those of control group (t=2.408, P=0.018; χ2=4.366, P=0.037). The incidence of adverse reaction of observation group and control group were 28.57% (12/42) and 33.33% (14/42), and there was no significant difference between the two groups (χ2=0.637, P=0.223). The follow-up results showed that, the 1 years survival rate, 2 year survival rate, 3 year survival rates in the observation group were 97.67%, 90.70% and 83.72%, while the control group were 95.24%, 83.33%, 57.14%, respectively. The 1, 2 year survival rate showed no significant difference between two groups (P>0.05), but the 3 year survival rate of observation group was significantly higher than that of the control group (χ2=8.400, P=0.004). Moreover, the overall survival time of the observation group was significantly higher than that of the control group (t=15.531, P=0.000), and the local recurrence rate and metastasis rate were also significantly lower than the control group (χ2=5.143, P=0.023). Conclusion Lobaplatin neoadjuvant intraarterial chemotherapy combined with limb salvage operation has good long-term and short-term effects on the osteosarcoma. |
| keywords:Osteosarcoma Limb salvage operation Lobaplatin Neoadjuvant chemotherapy Arterial infusion |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
